Release Date: 02/03/16 09:14 Summary: Class - 100,000 Portfolios Price Sensitive: Yes Download Document 158.04KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%